QR-koodi

Fruquintinib and sintilimab plus SOX as perioperative therapy for locally resectable advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase II clinical trial

BackgroundLocally advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma faces high recurrence risks despite radical surgery. Perioperative chemotherapy (e.g., FLOT regimen) improves survival but has limited pathological complete response (pCR) rates and significant toxicity. Immunotherap...

Täydet tiedot

Tallennettuna:
Päätekijät: Xiangyu Meng, Dong Yang, Yuanlin Liu, Chao Wang, Junqiao Yao, Tao Zhang
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2025-07-01
Sarja:Frontiers in Immunology
Aiheet:
G/GEJ adenocarcinoma
perioperative treatment
fruquintinib
sintilimab
effectiveness
Linkit:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1638316/full
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia